###begin article-title 0
###xml 53 58 <span type="species:ncbi:9606">Human</span>
Phenotypic Studies of Natural Killer Cell Subsets in Human Transporter Associated with Antigen Processing Deficiency
###end article-title 0
###begin p 1
Conceived and designed the experiments: AM JZ Hd. Performed the experiments: AM JZ HB. Analyzed the data: AM JZ EA FH HB LD DH Hd. Contributed reagents/materials/analysis tools: AM EA LD. Wrote the paper: AM JZ Hd.
###end p 1
###begin p 2
###xml 294 300 294 300 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 815 817 815 817 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">51</sup>
###xml 935 941 935 941 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 1094 1097 1094 1097 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 1101 1102 1101 1102 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1590 1596 1590 1596 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 48 56 <span type="species:ncbi:9606">patients</span>
###xml 337 345 <span type="species:ncbi:9606">patients</span>
###xml 403 411 <span type="species:ncbi:9606">patients</span>
###xml 471 479 <span type="species:ncbi:9606">patients</span>
###xml 921 929 <span type="species:ncbi:9606">patients</span>
###xml 1043 1051 <span type="species:ncbi:9606">patients</span>
###xml 1291 1299 <span type="species:ncbi:9606">patients</span>
Peripheral blood natural killer (NK) cells from patients with transporter associated with antigen processing (TAP) deficiency are hyporesponsive. The mechanism of this defect is unknown, but the phenotype of TAP-deficient NK cells is almost normal. However, we noticed a high percentage of CD56bright cells among total NK cells from two patients. We further investigated TAP-deficient NK cells in these patients and compared them to NK cells from two other TAP-deficient patients with no clinical symptoms and to individuals with chronic inflammatory diseases other than TAP deficiency (chronic lung diseases or vasculitis). Peripheral blood mononuclear cells isolated from venous blood were stained with fluorochrome-conjugated antibodies and the phenotype of NK cells was analyzed by flow cytometry. In addition, 51Chromium release assays were performed to assess the cytotoxic activity of NK cells. In the symptomatic patients, CD56bright NK cells represented 28% and 45%, respectively, of all NK cells (higher than in healthy donors). The patients also displayed a higher percentage of CD56dimCD16- NK cells than controls. Interestingly, this unusual NK cell subtype distribution was not found in the two asymptomatic TAP-deficient cases, but was instead present in several of the other patients. Over-expression of the inhibitory receptor CD94/NKG2A by TAP-deficient NK cells was confirmed and extended to the inhibitory receptor ILT2 (CD85j). These inhibitory receptors were not involved in regulating the cytotoxicity of TAP-deficient NK cells. We conclude that expansion of the CD56bright NK cell subtype in peripheral blood is not a hallmark of TAP deficiency, but can be found in other diseases as well. This might reflect a reaction of the immune system to pathologic conditions. It could be interesting to investigate the relative distribution of NK cell subsets in various respiratory and autoimmune diseases.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 65 66 65 66 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 70 71 70 71 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 251 254 251 254 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 258 264 258 264 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 310 313 310 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Cooper1">[1]</xref>
###xml 360 366 360 366 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 414 415 414 415 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 431 437 431 437 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 449 452 449 452 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 468 474 468 474 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 485 488 485 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Cooper1">[1]</xref>
###xml 531 534 531 534 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 538 539 538 539 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 559 560 559 560 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 564 565 564 565 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 596 599 596 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Mavilio1">[2]</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human natural killer (NK) cells are phenotypically defined as CD3-CD56+ lymphocytes. They constitute a heterogeneous blood cell population and subsets can be defined depending on their level of expression of CD16 and CD56. In healthy individuals, CD56dimCD16bright cells represent at least 90% of all NK cells [1]. Most of the other NK cells belong to the CD56bright subset that can be further subdivided in a CD16- (30-50% of CD56bright) and a CD16dim (50-70% of CD56bright) fraction [1]. Finally, minor subpopulations with a CD56dimCD16- and conversely CD56-CD16+ phenotype have been described [2].
###end p 4
###begin p 5
###xml 265 268 265 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Smyth1">[3]</xref>
###xml 269 272 269 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-OConnor1">[5]</xref>
###xml 984 987 984 987 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Lanier1">[4]</xref>
###xml 989 992 989 992 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-OConnor1">[5]</xref>
###xml 1090 1093 1090 1093 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Kumar1">[6]</xref>
###xml 470 475 <span type="species:ncbi:9606">human</span>
The major functional properties of NK cells are cytotoxicity and cytokine production, which are governed by a balance between activating messages transmitted by activating receptors (AR) and inhibitory signals transmitted by inhibitory receptors (IR), respectively [3]-[5]. Activating receptors recognize ligands expressed by tumor cells or stressed cells or, in the case of CD16, antibodies (Ab) of the IgG class bound to target cells. Among the IR, those specific for human leukocyte antigen (HLA) class I molecules recognize either (i) restricted numbers of classical HLA class I alleles in the case of killer immunoglobulin receptors (KIR), (ii) a broad panel of classical HLA class I molecules as well as HLA-G in the case of immunoglobulin-like transcript 2 (ILT2 or CD85j) and (iii) the non classical major histocompatibility complex (MHC) class I molecule HLA-E presenting peptides derived from the signal sequence of classical HLA class I molecules in the case of CD94/NKG2A [4], [5]. In addition, NK cells express also several IR with ligands different from HLA class I molecules [6].
###end p 5
###begin p 6
###xml 66 67 66 67 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 182 185 182 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Gromm1">[7]</xref>
###xml 186 189 186 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-York1">[9]</xref>
###xml 734 737 734 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Gromm1">[7]</xref>
###xml 738 741 738 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-York1">[9]</xref>
HLA class I molecules present endogenous peptides to cytotoxic CD8+ T cells. Newly synthesized HLA class I molecules acquire their peptidic ligands in the endoplasmic reticulum (ER) [7]-[9]. Most of these peptides that result from the degradation of endogenous proteins by the proteasome are translocated into the lumen of the ER by the transporter associated with antigen processing (TAP). TAP is expressed as a heterodimer of two subunits, TAP1 and TAP2, and is inserted in the membrane of the ER. In the absence of a functional TAP, only a very limited amount of peptides can reach the lumen of the ER and associate with HLA class I molecules. Consequently, most of these molecules remain unstable and never reach the cell surface [7]-[9].
###end p 6
###begin p 7
###xml 67 71 67 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-DelaSalle1">[10]</xref>
###xml 72 76 72 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Dogu1">[23]</xref>
###xml 234 238 234 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Zimmer1">[11]</xref>
###xml 240 244 240 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-DelaSalle4">[21]</xref>
###xml 276 280 276 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Zimmer1">[11]</xref>
###xml 282 286 282 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Plebani1">[18]</xref>
###xml 534 538 534 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-DelaSalle1">[10]</xref>
###xml 540 544 540 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Zimmer1">[11]</xref>
###xml 633 637 633 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Parissiadis1">[22]</xref>
###xml 639 643 639 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Dogu1">[23]</xref>
###xml 998 999 990 991 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1072 1076 1064 1068 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-DelaSalle1">[10]</xref>
###xml 1078 1082 1070 1074 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Zimmer1">[11]</xref>
###xml 9 14 <span type="species:ncbi:9606">human</span>
###xml 309 317 <span type="species:ncbi:9606">patients</span>
###xml 725 733 <span type="species:ncbi:9606">patients</span>
Nineteen human cases of TAP deficiency have to date been described [10]-[23]. Clinically, this recessive autosomal disease is very heterogeneous, the spectrum of possible manifestations extending from the complete absence of symptoms [11], [21] to life-threatening conditions [11], [18]. Most frequently, the patients suffer from chronic bacterial infections of the upper and lower airways, evolving to bronchiectasis, and in approximately half of the cases also from skin ulcers with features of a chronic granulomatous inflammation [10], [11]. Recent observations also describe the occurrence of ocular and pulmonary toxoplasmosis [22], [23]. Surprisingly however, severe viral infections have never been reported in these patients, despite the defect in HLA class I-mediated presentation of viral antigens to cytotoxic T cells. It is assumed that other antiviral defense mechanisms like antibodies, non HLA class I-restricted cytotoxic effector cells (gammadelta T lymphocytes, NK cells) and CD8+ T cell responses to TAP-independent antigens are sufficiently efficient [10], [11].
###end p 7
###begin p 8
###xml 170 174 170 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-DelaSalle1">[10]</xref>
###xml 176 180 176 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Zimmer1">[11]</xref>
###xml 283 286 283 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Lanier1">[4]</xref>
###xml 444 445 444 445 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 527 528 527 528 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 828 832 828 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Zimmer2">[24]</xref>
###xml 854 858 854 858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Zimmer3">[25]</xref>
###xml 987 991 987 991 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Zimmer2">[24]</xref>
###xml 1033 1037 1033 1037 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Zimmer2">[24]</xref>
###xml 1039 1043 1039 1043 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Vitale1">[26]</xref>
###xml 1076 1077 1076 1077 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 16 24 <span type="species:ncbi:9606">patients</span>
###xml 397 405 <span type="species:ncbi:9606">patients</span>
###xml 776 794 <span type="species:ncbi:10376">Epstein-Barr virus</span>
###xml 796 799 <span type="species:ncbi:10376">EBV</span>
The symptomatic patients have a very large (30- to 100-fold) reduction in the cell surface expression levels of HLA class I molecules, as compared to healthy individuals [10], [11]. As NK cells preferentially kill target cells with low or absent HLA class I molecules on the surface [4], we previously investigated susceptibility of autologous cells to NK cell-mediated lysis in two TAP-deficient patients. TAP-deficient cells are killed by TAP+ normal NK cells but not by autologous resting NK cells. Nevertheless, resting TAP- NK cells are able to perform antibody-dependent cellular cytotoxicity (ADCC) to some extent, and after stimulation with interleukin (IL) 2, they become cytotoxic not only towards tumor cell lines, but also to two types of autologous cells, namely Epstein-Barr virus (EBV)-transformed B lymphoblasts [24] and skin fibroblasts [25]. Their repertoire of AR and IR is almost normal, although CD94/NKG2A is expressed at much higher levels than by normal NK cells [24]. Not only AR, but also IR are functional [24], [26], as assessed using activated TAP- NK cells in cytotoxicity tests against allogeneic normal cells. Thus, the mechanism responsible for the hyporesponsiveness of resting TAP-deficient NK cells is still unknown.
###end p 8
###begin p 9
###xml 77 83 77 83 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 119 123 119 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Vitale1">[26]</xref>
###xml 201 207 201 207 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 518 522 518 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-DelaSalle4">[21]</xref>
###xml 100 108 <span type="species:ncbi:9606">patients</span>
###xml 469 477 <span type="species:ncbi:9606">patients</span>
###xml 509 517 <span type="species:ncbi:9606">patients</span>
###xml 654 662 <span type="species:ncbi:9606">patients</span>
Previous investigations also revealed a higher than normal percentage of CD56bright cells among the patients' NK cells [26]. The objective of our study was to investigate if the high percentage of CD56bright NK cells and the over-expression of NKG2A were constant findings in TAP deficiency, and if these features could also be observed in diseases of other origins. Therefore, we compared by flow cytometry peripheral blood NK cells from the symptomatic TAP-deficient patients to those from two asymptomatic patients [21] as well as to a small panel of individuals with respiratory diseases of etiologies different from TAP deficiency and of vasculitis patients. A group of normal control donors was also included.
###end p 9
###begin title 10
Methods
###end title 10
###begin title 11
###xml 0 12 <span type="species:ncbi:9606">Participants</span>
Participants
###end title 11
###begin p 12
###xml 47 55 <span type="species:ncbi:9606">patients</span>
###xml 341 349 <span type="species:ncbi:9606">patients</span>
###xml 365 373 <span type="species:ncbi:9606">patients</span>
Blood samples were obtained from volunteers or patients attending the clinics of Strasbourg University Hospitals and were collected during routine clinical (diagnostic/prognostic/therapeutic) procedures prescribed by two co-authors, Pr. E. Andres and Dr. L. Donato. Before blood samples were collected for the study, all healthy donors, all patients and, for those patients who were minor at the time of blood sampling, their parents, gave written informed consent in agreement with the Helsinki Declaration and French legislation, under which no approval by an Ethics Committee was required in this case.
###end p 12
###begin p 13
###xml 54 58 54 58 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-DelaSalle2">[12]</xref>
###xml 60 64 60 64 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-DelaSalle4">[21]</xref>
###xml 17 25 <span type="species:ncbi:9606">patients</span>
###xml 70 78 <span type="species:ncbi:9606">patients</span>
###xml 114 122 <span type="species:ncbi:9606">patients</span>
###xml 195 203 <span type="species:ncbi:9606">patients</span>
###xml 282 290 <span type="species:ncbi:9606">patients</span>
###xml 729 737 <span type="species:ncbi:9606">patients</span>
We included four patients with a known TAP deficiency [12], [21], two patients with a known cystic fibrosis, five patients with chronic respiratory diseases complicated by acute infections, five patients with chronic respiratory diseases but no acute infection, and five vasculitis patients. The inclusion in one or another group was decided on the basis of clinical and biological parameters by the above mentioned physicians. As our study was intended as preliminary and as potential indicator for the interest of future large scale investigations, we deliberately limited the size of the different groups, and no sample size calculations were performed. In addition, we included seventeen volunteer donors (the same number as patients with no TAP deficiency) with no apparent signs of disease.
###end p 13
###begin title 14
Flow cytometry
###end title 14
###begin p 15
###xml 230 234 <span type="species:ncbi:9913">calf</span>
Peripheral blood mononuclear cells (PBMC) were isolated from citrated venous blood by Ficoll-Hypaque density gradient centrifugation and either used directly for flow cytometry or frozen in RPMI 1640 culture medium with 20% fetal calf serum (FCS) and 10% dimethylsulfoxyde (DMSO).
###end p 15
###begin p 16
###xml 225 226 219 220 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 432 439 422 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001033-t001">table 1</xref>
###xml 709 713 699 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Sivori1">[27]</xref>
###xml 1009 1013 <span type="species:ncbi:9925">goat</span>
###xml 1019 1024 <span type="species:ncbi:10090">mouse</span>
###xml 1082 1087 <span type="species:ncbi:10090">mouse</span>
For flow cytometry stainings, PBMC were washed at 4degreesC, once in RPMI 1640/10% FCS and once in phosphate buffered saline (PBS) with 3% FCS (staining buffer). Cells were then resuspended in ice-cold staining buffer at 5x106 cells/ml and stained in aliquots of 100 microl with various purified or fluorochrome-conjugated Ab at optimal concentrations previously determined by titration. The Ab and fluorochromes used are listed in table 1. They were purchased from Beckman Coulter (Margency, France), with the exception of HP-F1 (anti-ILT2), generously provided by Pr. Miguel Lopez-Botet, University Pompeu Fabra, Barcelona, Spain, and Z199 (anti-NKG2A), produced in one of our labs and previously described [27]. After incubation in the dark, at 4degreesC, for 30 minutes, cells were washed twice in ice-cold staining buffer and fixed in Cytofix solution (BD Biosciences, Erembodegem, Belgium). In the case of cells first stained with purified Ab, they were washed, incubated with a secondary PE-conjugated goat anti-mouse Ab (Dako, Glostrup, Denmark), washed again, incubated in mouse serum for 20 minutes, washed once more, and finally stained with fluorochrome-conjugated Ab as described above. Stained cells were kept in the dark at 4degreesC until flow cytometry, that was performed on a FACSCaliburtrade mark flow cytometer (BD Biosciences). Results were analyzed with Cellquesttrade mark software (BD Biosciences). The region of living lymphocytes was gated based on forward and side scatter characteristics, and at least 2500 NK cells per sample were acquired.
###end p 16
###begin title 17
Antibodies used for flow cytometry
###end title 17
###begin p 18
###xml 208 212 <span type="species:ncbi:9925">goat</span>
###xml 218 223 <span type="species:ncbi:10090">mouse</span>
FITC : fluorescein isothiocyanate ; PE : phycoerythrin ; PC5 : phycoerythrin-cyanin 5. *: indirect staining; cells were first stained with the indicated purified Ab, washed, and then stained with a secondary goat anti-mouse Ab conjugated to PE. All other Ab were used in directly fluorochrome-conjugated forms.
###end p 18
###begin title 19
Cytotoxicity Assays
###end title 19
###begin p 20
###xml 119 123 119 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Vitale1">[26]</xref>
###xml 188 190 188 190 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">51</sup>
###xml 253 257 253 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Zimmer2">[24]</xref>
###xml 259 263 259 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Vitale1">[26]</xref>
Activated NK cells and phytohemagglutinin (PHA)-induced T cell blasts were obtained in culture as previously described [26]. For the assessment of NK cell cytotoxicity, standard four hour 51Chromium release assays were performed as previously described [24], [26] in the absence or presence of masking Ab used at a concentration of 10 microg/ml.
###end p 20
###begin title 21
Results
###end title 21
###begin title 22
###xml 23 29 23 29 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 47 55 <span type="species:ncbi:9606">patients</span>
High percentage of CD56bright NK cells in some patients with TAP deficiency but also chronic diseases of other origins
###end title 22
###begin p 23
###xml 77 83 77 83 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 123 127 123 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Vitale1">[26]</xref>
###xml 262 263 262 263 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 267 268 267 268 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 325 331 325 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">versus</italic>
###xml 361 369 361 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001033-g001">figure 1</xref>
###xml 377 384 377 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001033-t002">table 2</xref>
###xml 461 467 461 467 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 508 514 508 514 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 571 572 571 572 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 581 584 581 584 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 625 628 625 628 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 735 738 735 738 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 742 743 742 743 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 754 761 754 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001033-t002">table 2</xref>
###xml 114 122 <span type="species:ncbi:9606">patients</span>
###xml 418 426 <span type="species:ncbi:9606">patients</span>
###xml 596 603 <span type="species:ncbi:9606">patient</span>
###xml 659 666 <span type="species:ncbi:9606">patient</span>
###xml 690 698 <span type="species:ncbi:9606">patients</span>
To confirm and extend our previous findings about the high percentage of CD56bright NK cells in two TAP-deficient patients [26], we stained PBMC from these individuals and from seven healthy donors with anti-CD3, -CD19, -CD16 and -CD56 Ab. Within the gate of CD3-CD19- lymphocytes corresponding to NK cells, we analyzed CD16 versus CD56 expression. As shown in figure 1 and in table 2, it appeared indeed that the two patients had a very high percentage of CD56bright NK cells compared to normal donors. CD56bright NK cells were distributed quite equally between the CD16- and CD16dim subsets in patient EMO, whereas the CD16dim population was predominant in patient EFA. In addition, both patients also had a higher percentage of CD56dimCD16- NK cells (table 2).
###end p 23
###begin title 24
###xml 24 30 24 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 73 81 <span type="species:ncbi:9606">patients</span>
High percentages of CD56bright NK cells in two symptomatic TAP-deficient patients.
###end title 24
###begin p 25
###xml 180 181 180 181 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 185 186 185 186 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 251 257 251 257 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 37 45 <span type="species:ncbi:9606">patients</span>
PBMC from four normal donors and the patients were stained with fluorochrome-conjugated antibodies and analyzed by flow cytometry. Expression of CD16 and CD56 is shown on gated CD3-CD19- lymphocytes (one representative experiment). Percentages of CD56bright NK cells among total NK cells are indicated for each donor.
###end p 25
###begin title 26
###xml 33 41 <span type="species:ncbi:9606">patients</span>
NK cell subsets in TAP-deficient patients and healthy control donors
###end title 26
###begin p 27
###xml 151 159 <span type="species:ncbi:9606">patients</span>
###xml 210 218 <span type="species:ncbi:9606">patients</span>
###xml 269 277 <span type="species:ncbi:9606">patients</span>
Values correspond to the cells in the different subsets expressed as percentages of total peripheral blood NK cells. HD: healthy donor; EHA: father of patients EFA and EMO; EFA, EMO: symptomatic TAP2-deficient patients (siblings); SFH, DFH: asymptomatic TAP2-deficient patients (siblings).
###end p 27
###begin p 28
###xml 7 13 7 13 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 51 54 51 54 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 64 67 64 67 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Cooper1">[1]</xref>
###xml 69 73 69 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Jacobs1">[28]</xref>
###xml 425 429 425 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-DelaSalle4">[21]</xref>
###xml 456 462 456 462 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 542 549 542 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001033-t002">table 2</xref>
###xml 627 630 627 630 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 634 635 634 635 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 114 122 <span type="species:ncbi:9606">patients</span>
###xml 403 411 <span type="species:ncbi:9606">patients</span>
As CD56bright NK cells are less cytotoxic than CD56dim NK cells [1], [28], their high percentage in TAP-deficient patients might reflect an adaptation to the low HLA class I expression in order to avoid cytotoxicity toward autologous targets. In that case, a similar distribution of NK cell subsets should be observed in other TAP-deficient individuals. Therefore, we looked at PBMC from two additional patients, SFH and DFH [21], and found that their CD56bright NK cells represented 8% and 4% of all peripheral blood NK cells, respectively (table 2). They were thus within the normal range (<10% of NK cells), as were the CD56dimCD16- cells.
###end p 28
###begin p 29
###xml 52 58 52 58 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 196 202 196 202 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 441 447 441 447 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 93 101 <span type="species:ncbi:9606">patients</span>
###xml 157 165 <span type="species:ncbi:9606">patients</span>
###xml 323 331 <span type="species:ncbi:9606">patients</span>
###xml 341 349 <span type="species:ncbi:9606">patients</span>
###xml 480 488 <span type="species:ncbi:9606">patients</span>
In the absence of a systematic expansion of the CD56bright NK cell fraction in TAP-deficient patients, an alternative explanation for the values observed in patients EFA and EMO could be that CD56bright NK cells become more abundant as a reaction to an acute infection or to the chronic inflammatory state present in these patients (whereas patients SFH and DFH were asymptomatic). Should this be true, higher than normal percentages of CD56bright NK cells might also be found in patients with no TAP deficiency but with acute or chronic infections and/or inflammatory diseases of other origins.
###end p 29
###begin p 30
###xml 154 161 154 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001033-t003">table 3</xref>
###xml 377 384 377 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001033-t004">table 4</xref>
###xml 454 460 454 460 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 635 638 635 638 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 642 643 642 643 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 768 774 768 774 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 797 804 797 804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001033-t004">table 4</xref>
###xml 68 76 <span type="species:ncbi:9606">patients</span>
###xml 131 139 <span type="species:ncbi:9606">patients</span>
###xml 548 556 <span type="species:ncbi:9606">patients</span>
###xml 692 700 <span type="species:ncbi:9606">patients</span>
We thus repeated the stainings described above in a small series of patients mentioned in the Methods section. Details about these patients are listed in table 3. HLA class I deficiency was ruled out in all of them by flow cytometry staining of PBMC with the pan anti-HLA class I Ab W6/32 (data not shown). We also included a panel of healthy donors. The results summarized in table 4 revealed, in accordance with our hypothesis, a percentage of the CD56bright population clearly above 10% of all peripheral blood NK cells in five of the seventeen patients (29.41%) and even in three of the ten healthy donors (30%). Regarding the CD56dimCD16- NK cell subtype, it was higher than 10% in four patients (23.53%), of whom only one also displayed a high percentage of CD56bright NK cells in parallel (table 4).
###end p 30
###begin title 31
###xml 19 27 <span type="species:ncbi:9606">patients</span>
Characteristics of patients with diseases other than TAP deficiency
###end title 31
###begin p 32
age*: age at the time of blood sampling; F: female; M: male; COPD: chronic obstructive pulmonary disease.
###end p 32
###begin title 33
###xml 49 57 <span type="species:ncbi:9606">patients</span>
NK cell subsets in additional healthy donors and patients with diseases other than TAP deficiency
###end title 33
###begin p 34
###xml 58 65 58 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001033-t002">table 2</xref>
###xml 133 140 133 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001033-t003">table 3</xref>
###xml 74 82 <span type="species:ncbi:9606">patients</span>
HD 8-HD 17: healthy donors (different from those shown in table 2); 1-17: patients 1-17 with diseases other than TAP deficiency (see table 3 for details).
###end p 34
###begin title 35
###xml 37 43 37 43 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 52 55 52 55 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 88 96 <span type="species:ncbi:9606">patients</span>
Over-expression of NKG2A on both CD56bright and CD56dim NK cells from two TAP-deficient patients
###end title 35
###begin p 36
###xml 99 103 99 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Zimmer2">[24]</xref>
###xml 395 401 395 401 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 414 417 414 417 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 427 430 427 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Cooper1">[1]</xref>
###xml 432 436 432 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Jacobs1">[28]</xref>
###xml 551 557 551 557 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 922 923 922 923 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 927 928 927 928 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 932 933 932 933 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 954 960 954 960 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 1153 1156 1153 1156 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 1202 1203 1202 1203 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1772 1778 1772 1778 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 1787 1790 1787 1790 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 1801 1809 1801 1809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001033-g002">figure 2</xref>
###xml 1888 1891 1888 1891 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 1905 1911 1905 1911 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 1988 1996 1988 1996 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001033-g002">figure 2</xref>
###xml 2119 2125 2119 2125 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 2241 2244 2241 2244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Cooper1">[1]</xref>
###xml 2246 2250 2246 2250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Jacobs1">[28]</xref>
###xml 2296 2302 2296 2302 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 2320 2323 2320 2323 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 2491 2497 2491 2497 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 78 86 <span type="species:ncbi:9606">patients</span>
###xml 215 223 <span type="species:ncbi:9606">patients</span>
###xml 739 747 <span type="species:ncbi:9606">patients</span>
###xml 1051 1059 <span type="species:ncbi:9606">patients</span>
###xml 1427 1435 <span type="species:ncbi:9606">patients</span>
###xml 1574 1582 <span type="species:ncbi:9606">patients</span>
###xml 1962 1970 <span type="species:ncbi:9606">patients</span>
###xml 2074 2082 <span type="species:ncbi:9606">patients</span>
###xml 2655 2663 <span type="species:ncbi:9606">patients</span>
The previously reported over-expression of the IR CD94/NKG2A by NK cells from patients EFA and EMO [24] could likewise be interpreted as an adaptation of NK cells to the low levels of HLA class I molecules in these patients, because it might allow to avoid autoreactivity, at least to some extent. However, as it is known that mean fluorescence intensities (MFI) of NKG2A are much higher on CD56bright than on CD56dim NK cells [1], [28], the observed over-expression of NKG2A in EFA and EMO might simply be a consequence of the high percentage of CD56bright NK cells and would not necessarily reflect a regulatory mechanism. To address this point, we stained PBMC from EFA and EMO, SFH, DFH, the seventeen healthy donors and the seventeen patients with diseases other than TAP deficiency with anti-CD3, -CD19, -CD56 and -NKG2A Ab and analyzed NKG2A expression in terms of percentages of positive cells and MFI on gated CD3-CD19-CD56+ NK cells. Among CD56bright NK cells, more than 90% expressed NKG2A in the vast majority of healthy donors as well as patients (mean: 90.75%, range: 56-100%). Much more inter-individual differences were observed for CD56dim NK cells, of whom a mean of 49.37% were NKG2A+ (range: 20-77%). To compare MFI, we randomly designed a healthy donor whose values of NKG2A MFI on both NK cell subsets were arbitrarily considered to be 100%. The values measured in all the other control donors and in the patients were then expressed relative to this reference value, and we calculated means of MFI for the different subject groups (healthy donors and patients, the latter grouped according to similar disease states). Interestingly, it appeared that NK cells from EFA and EMO, but not from SFH and DFH, dramatically over-expressed NKG2A on both CD56bright and CD56dim NK cells (figure 2). The difference to the other subject groups was even more pronounced for CD56dim than for CD56bright NK cells. Mean values of healthy donors and other patients were much lower (figure 2). When looking at every individual, none of the healthy donors and the other patients, including those with increased CD56bright percentages, displayed such high MFI of NKG2A on either subset (data not shown). In accordance with the literature [1], [28], the higher expression level of NKG2A on CD56bright, compared to CD56dim NK cells, was clearly confirmed in each individual except EFA and EMO with comparable MFI on both subsets (data not shown). Thus, in contrast to the proportion of CD56bright NK cells that might increase in several different pathologic conditions, over-expression of NKG2A was found exclusively in the two symptomatic TAP-deficient patients.
###end p 36
###begin title 37
###xml 46 52 46 52 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 61 64 61 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 110 118 <span type="species:ncbi:9606">patients</span>
Dramatic over-expression of NKG2A on both CD56bright and CD56dim NK cell subsets of symptomatic TAP-deficient patients.
###end title 37
###begin p 38
###xml 255 263 <span type="species:ncbi:9606">patients</span>
###xml 287 295 <span type="species:ncbi:9606">patients</span>
###xml 455 463 <span type="species:ncbi:9606">patients</span>
###xml 502 510 <span type="species:ncbi:9606">patients</span>
Mean fluorescence intensities (MFI) of NKG2A were expressed relative to the values of a randomly chosen healthy donor arbitrarily considered as 100%. Mean values of different subject groups were calculated. ND: normal donors (n = 17); CF: cystic fibrosis patients (N = 2), V: vasculitis patients (n = 5), inf. R.I.: infected respiratory insufficiency (n = 5), uninf. R.I.: uninfected respiratory insufficiency (n = 5); EFA, EMO: symptomatic TAP-deficient patients; DFH, SFH: asymptomatic TAP-deficient patients.
###end p 38
###begin title 39
###xml 93 101 <span type="species:ncbi:9606">patients</span>
The inhibitory receptor ILT2 is over-expressed in symptomatic and asymptomatic TAP-deficient patients
###end title 39
###begin p 40
###xml 268 272 268 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Zimmer2">[24]</xref>
###xml 307 310 307 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Cooper1">[1]</xref>
###xml 312 316 312 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Jacobs1">[28]</xref>
###xml 380 383 380 383 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 417 418 417 418 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 538 541 538 541 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 588 591 588 591 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 818 826 818 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001033-g003">figure 3</xref>
###xml 259 267 <span type="species:ncbi:9606">patients</span>
###xml 771 779 <span type="species:ncbi:9606">patients</span>
###xml 979 987 <span type="species:ncbi:9606">patients</span>
###xml 1065 1073 <span type="species:ncbi:9606">patients</span>
###xml 1155 1163 <span type="species:ncbi:9606">patients</span>
###xml 1260 1268 <span type="species:ncbi:9606">patients</span>
We asked if the broad spectrum IR ILT2 might likewise be over-expressed at the surface of TAP-deficient NK cells, whereas we had previously shown that members of the KIR family, with a restricted number of HLA class I ligands, are normally expressed in these patients [24]. As previously reported by others [1], [28], ILT2 was predominantly, but not exclusively, expressed by CD56dim NK cells, and percentages of ILT2+ NK cells considerably differed between donors. Regarding the expression levels of ILT2, that we considered only on CD56dim NK cells, they were strongly augmented on CD56dim NK cells from EFA, EMO and DFH, although not as importantly as for NKG2A. SFH NK cells also over-expressed ILT2 to some extent compared to the mean of MFI from healthy donors and patients other than those with TAP deficiency (figure 3). Mean values of different subject groups were calculated in the same way as for NKG2A (see above). At the individual level, one control donor and five patients had MFI higher than SFH but clearly lower than the three other TAP-deficient patients. Interestingly, MFI of ILT2 on T cells, B cells and monocytes from TAP-deficient patients were not increased but were in the range of the values seen in the healthy donors and the other patients (data not shown), which suggests that the over-expression of ILT2 specifically by NK cells might have some biological significance. Even if care should be taken in the context of the low number of TAP-deficient individuals included in this study, our results nevertheless indicate that ILT2 over-expression might be a more consistent finding in this disease than NKG2A over-expression, and that it might be less dependent on the presence of clinical symptoms.
###end p 40
###begin title 41
###xml 31 34 31 34 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 76 84 <span type="species:ncbi:9606">patients</span>
Over-expression of ILT2 on CD56dim NK cells of symptomatic and asymptomatic patients.
###end title 41
###begin p 42
###xml 254 262 <span type="species:ncbi:9606">patients</span>
###xml 286 294 <span type="species:ncbi:9606">patients</span>
###xml 454 462 <span type="species:ncbi:9606">patients</span>
###xml 501 509 <span type="species:ncbi:9606">patients</span>
Mean fluorescence intensities (MFI) of ILT2 were expressed relative to the values of a randomly chosen control donor arbitrarily considered as 100%. Mean values of different subject groups were calculated. ND: normal donors (n = 17); CF: cystic fibrosis patients (N = 2), V: vasculitis patients (n = 5), inf. R.I.: infected respiratory insufficiency (n = 5), uninf. R.I.: uninfected respiratory insufficiency (n = 5); EFA, EMO: symptomatic TAP-deficient patients; DFH, SFH: asymptomatic TAP-deficient patients.
###end p 42
###begin title 43
Lysis of TAP-deficient PHA-induced T cell blasts is not restored by antibodies masking autologous NK cell inhibitory receptors
###end title 43
###begin p 44
###xml 27 31 27 31 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Zimmer2">[24]</xref>
###xml 33 37 33 37 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Zimmer3">[25]</xref>
###xml 448 452 448 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Vitale1">[26]</xref>
###xml 695 699 695 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Vitale1">[26]</xref>
###xml 808 816 808 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001033-g004">figure 4</xref>
###xml 930 938 930 938 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001033-g004">figure 4</xref>
###xml 1346 1354 1346 1354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001033-g004">figure 4</xref>
###xml 81 89 <span type="species:ncbi:9606">patients</span>
###xml 115 118 <span type="species:ncbi:10376">EBV</span>
###xml 313 321 <span type="species:ncbi:9606">patients</span>
###xml 543 550 <span type="species:ncbi:9606">patient</span>
###xml 1212 1219 <span type="species:ncbi:9606">patient</span>
We previously demonstrated [24], [25] that activated NK cells from TAP-deficient patients strongly lyse autologous EBV-transformed B lymphoblasts and skin fibroblasts. NK cell inhibitory receptors are therefore unlikely to play any protective role in this situation. In contrast, PHA-induced T cell blasts of the patients are resistant to autologous NK cell-mediated killing, whereas masking of HLA class I molecules with Ab does not restore lysis [26]. To complete these studies, we performed cytotoxicity assays with activated NK cells from patient EMO as effectors and autologous PHA-induced T cell blasts as targets, in the absence or presence of several Ab. Confirming our previous results [26], target cells were completely protected from lysis in the absence of Ab and in the presence of anti-HLA Ab (figure 4). Interestingly, killing did likewise not appear in the presence of masking Ab against KIR, ILT2 and CD94/NKG2A (figure 4), which suggests that HLA class I-specific IR, even the over-expressed ones, do not play a role in the protection of PHA-induced T cell blasts from autologous NK cell-mediated lysis. The results cannot be explained by a general resistance of PHA-induced T cell blasts from patient EMO to NK cell-mediated killing, because they were highly susceptible to activated NK cells from two normal unrelated donors (figure 4).
###end p 44
###begin title 45
TAP-deficient PHA-induced T cell blasts are resistant to killing by activated autologous NK cells even in the presence of antibodies masking inhibitory receptors.
###end title 45
###begin p 46
###xml 11 13 11 13 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">51</sup>
###xml 123 130 <span type="species:ncbi:9606">patient</span>
###xml 206 213 <span type="species:ncbi:9606">patient</span>
A standard 51Chromium release assay was performed with activated NK cells from two normal donors (NK ND A, NK ND B) and of patient EMO (NK EMO) as effectors and TAP-deficient PHA-induced T cell blasts from patient EMO as targets. The effector to target (E/T) ratio was 6/1. Masking Ab were used at a concentration of 10 microg/ml. Indicated values correspond to the percentages of specific lysis.
###end p 46
###begin title 47
###xml 33 39 33 39 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 104 112 <span type="species:ncbi:9606">patients</span>
Progressive reduction of the CD56bright NK cell fraction with improved clinical status of TAP-deficient patients
###end title 47
###begin p 48
###xml 425 431 425 431 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 560 566 560 566 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 570 571 570 571 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 650 656 650 656 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 660 663 660 663 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 950 953 950 953 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 957 958 957 958 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1075 1081 1075 1081 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 22 30 <span type="species:ncbi:9606">patients</span>
###xml 449 457 <span type="species:ncbi:9606">patients</span>
###xml 794 801 <span type="species:ncbi:9606">patient</span>
###xml 876 883 <span type="species:ncbi:9606">patient</span>
###xml 1000 1007 <span type="species:ncbi:9606">patient</span>
###xml 1039 1046 <span type="species:ncbi:9606">patient</span>
The results shown for patients EFA and EMO were obtained with PBMC harvested at the time when their TAP deficiency was diagnosed and their respiratory symptoms were very severe. Clinical status progressively improved over the following years due to an intense therapeutic approach with repeated intravenous administration of antibiotics and chest physiotherapy. In parallel, we observed a reduction of the percentages of CD56bright NK cells in both patients, even if the values measured remained substantially higher than in healthy donors. Interestingly, CD56brightCD16- proportions remained globally unchanged, whereas the lower percentages of CD56brightCD16dim NK cells accounted for most of the lowering. Over time, expression levels of NKG2A strongly diminished in both NK cell subsets of patient EFA (yet remained higher than in normal NK cells), and only moderately in patient EMO. Reductions of MFI of ILT2 were modest. The percentage of CD56dimCD16- NK cells strongly decreased with time in patient EFA, but slightly increased in patient EMO. At least regarding CD56bright NK cells, the reduced percentage that parallels clinical improvement could be in favor of a link between the proportion of this subset among total NK cells and the intensity and severity of respiratory infections.
###end p 48
###begin title 49
Discussion
###end title 49
###begin p 50
###xml 59 63 59 63 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Vitale1">[26]</xref>
###xml 123 129 123 129 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 419 425 419 425 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 434 437 434 437 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 534 538 534 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-DelaSalle4">[21]</xref>
###xml 580 586 580 586 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 595 598 595 598 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 649 655 649 655 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 91 99 <span type="species:ncbi:9606">patients</span>
###xml 326 334 <span type="species:ncbi:9606">patients</span>
###xml 695 700 <span type="species:ncbi:9606">human</span>
In this paper, we confirm and extend our previous findings [26] that in two TAP2-deficient patients, the percentage of CD56bright NK cells among total peripheral blood NK cells is very high in comparison to healthy donors. To our knowledge, NK cell subset distribution has not yet been investigated in detail in TAP-deficient patients studied by other groups, so that it is currently unknown if the distribution of CD56bright and CD56dim NK cells is similar or not in these other cases. The two asymptomatic TAP-deficient individuals [21] display anyhow normal percentages of CD56bright and CD56dim NK cells and thus the increased proportion of CD56bright NK cells is not a constant hallmark of human TAP deficiency.
###end p 50
###begin p 51
###xml 67 73 67 73 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 289 295 289 295 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 549 555 549 555 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 912 918 912 918 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 162 170 <span type="species:ncbi:9606">patients</span>
###xml 186 194 <span type="species:ncbi:9606">patients</span>
Based on this finding, we reasoned that the high percentage of CD56bright NK cells could be a consequence of the chronic infectious and inflammatory state of the patients. Indeed, among patients with chronic inflammatory diseases other than TAP deficiency, approximately 30% displayed CD56bright percentages above 10% of total NK cells, although their values never reached those of the TAP-deficient individuals. Due to the small number and the heterogeneity of our series that was intended as part of a preliminary study, we cannot conclude if CD56bright NK cell percentages are preferentially increased in certain well-defined disease stages or subtypes, or if this might rather occur, irrespective of the underlying condition, in response to infections with particular but not all microorganisms. These points would be very interesting to address in future large scale studies, as well as the question if CD56bright NK cell expansions could be used as a prognostic marker for the short- or long-term outcome of some diseases.
###end p 51
###begin p 52
###xml 46 52 46 52 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 186 192 186 192 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 253 256 253 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Cooper1">[1]</xref>
###xml 258 262 258 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Robertson1">[29]</xref>
We were somehow surprised to observe high CD56bright NK cell percentages also among 30% of the healthy control donors we tested, as it is generally admitted that in this population, CD56bright NK cells do not exceed 10% of all peripheral blood NK cells [1], [29]. Information about acute infectious episodes preliminary to blood sampling is not available from the group of healthy donors. This finding would likewise benefit from being validated by much larger series of individuals, whereby the criteria for attribution of the "healthy donor" status should be carefully defined.
###end p 52
###begin p 53
###xml 18 24 18 24 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 189 195 189 195 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 284 288 284 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Carson1">[30]</xref>
###xml 320 324 320 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Cac1">[31]</xref>
###xml 521 527 521 527 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 565 568 565 568 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 743 749 743 749 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 758 762 758 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Shibata1">[32]</xref>
###xml 237 245 <span type="species:ncbi:9606">patients</span>
###xml 356 363 <span type="species:ncbi:9606">patient</span>
###xml 645 652 <span type="species:ncbi:9606">patient</span>
Expansions of CD56bright NK cells are known during reconstitution of the immune system after bone marrow grafts, where the first lymphocytes to reappear in peripheral blood usually are CD56bright NK cells, and these cells also expand in patients daily treated with a low dose of IL-2 [30]. More recently, Cac and Ballas [31] published the case of a female patient with recalcitrant periungual warts whose peripheral blood NK cells contrasted with the usual situation, as the vast majority of her NK cells were of the CD56bright type and only a minor subset was CD56dim. In an atypical case of X-SCID with Omenn syndrome-like manifestations, the patient displayed an increased number of peripheral blood NK cells, half of them being of the CD56bright subtype [32].
###end p 53
###begin p 54
###xml 218 224 218 224 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 265 268 265 268 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 504 510 504 510 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 743 747 743 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Carson1">[30]</xref>
###xml 749 753 749 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Nagler1">[33]</xref>
###xml 755 759 755 759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Andr1">[34]</xref>
###xml 774 780 774 780 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 789 792 789 792 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 883 886 883 886 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Cooper1">[1]</xref>
###xml 888 892 888 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Campbell1">[35]</xref>
###xml 951 957 951 957 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 1023 1026 1023 1026 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 1128 1131 1128 1131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Cooper1">[1]</xref>
###xml 1133 1137 1133 1137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Campbell1">[35]</xref>
###xml 1139 1143 1139 1143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Cooper2">[36]</xref>
###xml 1175 1179 1175 1179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Freud1">[37]</xref>
###xml 1281 1285 1281 1285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Cooper2">[36]</xref>
###xml 1364 1370 1364 1370 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 1413 1416 1413 1416 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 1491 1497 1491 1497 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 1506 1509 1506 1509 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 1584 1588 1584 1588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Wendt1">[38]</xref>
###xml 1324 1329 <span type="species:ncbi:9606">human</span>
The latter observations raise the question of the relationship between both peripheral blood NK cell subsets, which is quite a controversial issue still not clearly resolved. The two main views are that either (i) CD56bright NK cells are immature precursors of CD56dim NK cells, or that (ii) both NK cell types are functionally different, terminally differentiated effectors that arise from separate hematopoietic precursors. Cited arguments in favor of the former hypothesis are the small number of CD56bright NK cells in peripheral blood, their proliferation in the presence of picomolar concentrations of IL-2, the expression of the hematopoietic stem cell marker CD117, the low content of cytotoxic granules and the low cytotoxic activity [30], [33], [34]. However, CD56bright and CD56dim NK cells display very different repertoires of adhesion molecules and chemokine receptors [1], [35] and thus different migratory properties. In addition, CD56bright NK cells produce much higher amounts of cytokines than their CD56dim counterparts, so that both subtypes might well be distinct and specialized effector cell populations [1], [35], [36]. In a very recent review paper [37], the Caligiuri group, in contrast to previous data in favor of the distinct effector cell hypothesis [36], present a linear sequential model of human NK cell development, in which CD56bright NK cells would again be precursors of CD56dim NK cells. On the other hand, comparative microarrays between purified CD56bright and CD56dim NK cells are strongly in favor of the hypothesis of two distinct subtypes [38].
###end p 54
###begin p 55
###xml 192 198 192 198 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 700 706 700 706 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 736 740 736 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Kubo1">[39]</xref>
###xml 853 859 850 856 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 869 873 866 870 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Saraste1">[40]</xref>
###xml 938 941 935 938 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 1148 1154 1145 1151 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 1234 1237 1231 1234 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 582 587 <span type="species:ncbi:9606">child</span>
###xml 593 598 <span type="species:ncbi:9606">human</span>
###xml 615 620 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 765 773 <span type="species:ncbi:9606">patients</span>
The findings of our study do not allow to strengthen one rather than another of these models. If one considers that both NK cell types are distinct effectors, it could be conceivable that CD56bright NK cells are increased during infectious and/or inflammatory processes because the immune system is globally activated and high amounts of NK cell-derived cytokines are needed as part of the immune response. The corresponding NK cell subset would therefore expand in these situations before going back to baseline levels once the stimuli have disappeared. In support of this idea, a child with human herpes virus 6 (HHV-6)-associated acute necrotizing encephalopathy had a very high percentage of CD56bright NK cells in peripheral blood [39], and multiple sclerosis patients treated with IFN-beta display a progressive increase in the percentages of CD56bright NK cells [40]. Alternatively, during such disease states, the turnover of CD56dim NK cells might be very high and the number of new NK cells generated from bone marrow precursors would increase through a feedback mechanism. The consequence would then be a high percentage of immature CD56bright NK cell precursors that appear in peripheral blood to continuously replace CD56dim NK cells.
###end p 55
###begin p 56
###xml 48 54 48 54 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 224 230 224 230 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 239 242 239 242 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 375 378 375 378 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 561 565 561 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Zimmer2">[24]</xref>
###xml 965 969 965 969 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Kim1">[41]</xref>
###xml 970 974 970 974 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Anfossi1">[43]</xref>
###xml 1092 1096 1092 1096 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Kim1">[41]</xref>
###xml 1106 1110 1106 1110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Raulet1">[42]</xref>
###xml 1125 1129 1125 1129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Anfossi1">[43]</xref>
###xml 152 160 <span type="species:ncbi:9606">patients</span>
###xml 416 424 <span type="species:ncbi:9606">patients</span>
###xml 1256 1264 <span type="species:ncbi:9606">patients</span>
###xml 1403 1411 <span type="species:ncbi:9606">patients</span>
###xml 1731 1739 <span type="species:ncbi:9606">patients</span>
###xml 1789 1792 <span type="species:ncbi:10376">EBV</span>
In contrast to the increased percentages of CD56bright NK cells, over-expression of the IR NKG2A and ILT2 was exclusively observed in the TAP-deficient patients. The former molecule was dramatically up-regulated on both CD56bright and CD56dim NK cell subsets of the two symptomatic individuals, whereas ILT2 was over-expressed, although to a lesser extent than NKG2A, by CD56dim NK cells from all four TAP-deficient patients. Interestingly, the over-expression only implicates IR with a broad spectrum of HLA class I ligands, but no receptors of the KIR family [24] that have a more restricted panel of ligands. From a finalistic point of view, this could be interpreted as an adaptation of NK cells to the low HLA class I-expressing environment in which they develop, as a higher expression level of broad-spectrum IR might be able to still transmit enough inhibitory signals to the NK cells and thus contribute to self-tolerance. On the other hand, recent papers [41]-[43] have convincingly shown that NK cells have in fact to express IR for self MHC class I molecules to become "licensed" [41], "armed" [42] or "educated" [43] for functional activity, and that they remain "hyporesponsive" in their absence. Thus, as resting NK cells from TAP-deficient patients express such receptors but have no cytotoxic activity, one might postulate another "licensing mechanism" that would be deficient in these patients, or alternatively that HLA class I levels on surrounding cells would simply be too low to correctly educate NK cells. Further work is clearly needed to clarify these issues. However, it should also be taken into account that even resting TAP-deficient NK cells perform ADCC, and that IL-2-activated NK cells from these patients are cytotoxic towards tumor cell lines and some (EBV-transformed B cells and fibroblasts) but not other (PHA-induced T cell blasts) autologous targets, which suggests that they might have underwent some educational mechanism that partly failed because self-tolerance is not constantly maintained
###end p 56
###begin p 57
###xml 106 107 106 107 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sup>
###xml 115 116 115 116 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k</sup>
###xml 127 130 127 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 143 147 143 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Doucey1">[44]</xref>
###xml 249 252 249 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 416 420 416 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Doucey1">[44]</xref>
###xml 580 583 580 583 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 7 12 <span type="species:ncbi:10090">mouse</span>
In the mouse, it has been shown that the inhibitory NK cell receptor Ly49A interacts with its ligands H-2Dd or H-2Dk through a cis interaction [44], which means that receptor and ligand are closely associated in the membrane of a same NK cell. This cis interaction has important functional consequences and actually governs the inhibitory potential of Ly49A as well as its accessibility for tetramer and Ab staining [44]. It could thus be argued that NKG2A and/or ILT2 are not truly over-expressed in TAP deficiency, but that the lack of ligands and, consequently, the absence of cis interaction would render them simply more accessible for specific Ab. At least for NKG2A, this explanation seems rather unlikely, as (i) over-expression of NKG2A is not a constant finding in TAP deficiency, and (ii) expression levels diminish in parallel to clinical improvement. Regarding ILT2, the possibility still exists but would have to be tested in the context of the crystal structure of this receptor.
###end p 57
###begin p 58
###xml 423 427 423 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Vitale1">[26]</xref>
###xml 823 827 823 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Markel1">[20]</xref>
###xml 1130 1134 1130 1134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001033-Vitale1">[26]</xref>
###xml 674 677 <span type="species:ncbi:10376">EBV</span>
###xml 956 964 <span type="species:ncbi:9606">patients</span>
###xml 1030 1038 <span type="species:ncbi:9606">patients</span>
###xml 1121 1129 <span type="species:ncbi:9606">patients</span>
Although the over-expression of some IR might be an adaptive mechanism to the low levels of HLA class I expression, it does not seem to have any functional role in the regulation of the cytotoxic activity of IL2-activated TAP-deficient NK cells, as revealed by the absence of killing of autologous PHA-induced T cell blasts even in the presence of anti-IR masking Ab. These data, in accordance with our previous hypothesis [26], are in favor of the existence of an IR with ligands different from HLA class I molecules and that would be strongly expressed by activated TAP-deficient NK cells, the ligands being present on the surface of PHA-induced T cell blasts, but not of EBV-transformed B cells nor skin fibroblasts. With regard to the identity of this IR, additional investigations are required, although Markel et al. [20], who studied another family affected by TAP deficiency, have shown that CD66a or CEACAM1 is over-expressed by NK cells of these patients and functions as an IR protecting autologous cells. However, the patients also had a reduced expression level of the AR NKp46, which is not the case in our patients [26]. Thus, several different adaptive mechanisms of NK cells might exist according to the individual cases.
###end p 58
###begin p 59
###xml 192 198 192 198 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 587 593 587 593 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 610 617 610 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 137 145 <span type="species:ncbi:9606">patients</span>
###xml 287 295 <span type="species:ncbi:9606">patients</span>
In conclusion, in this paper, we provide data that extend our knowledge on the phenotype of peripheral blood NK cells from TAP-deficient patients. In addition, we show that percentages of CD56bright NK cells might exceed 10% of all peripheral blood NK cells in a substantial fraction of patients with chronic diseases other than TAP deficiency and even in donors considered as immunologically normal. Therefore, it might be recommendable to check more frequently the NK cell subset distribution in infectious and inflammatory diseases, in order to precise the conditions under which CD56bright NK cells expand in vivo, and what is the pathophysiological significance of this phenomenon.
###end p 59
###begin p 60
The authors would like to thank Pr. Miguel Lopez-Botet for kindly providing one of the antibodies (HP-F1, anti-ILT2) used in this study.
###end p 60
###begin title 61
References
###end title 61
###begin article-title 62
###xml 15 20 <span type="species:ncbi:9606">human</span>
The biology of human natural killer-cell subsets.
###end article-title 62
###begin article-title 63
###xml 104 107 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals.
###end article-title 63
###begin article-title 64
New aspects of natural-killer-cell surveillance and therapy of cancer.
###end article-title 64
###begin article-title 65
NK cell recognition.
###end article-title 65
###begin article-title 66
Putting the natural killer cell in its place.
###end article-title 66
###begin article-title 67
A new self: MHC-class-I-independent natural-killer-cell self-tolerance.
###end article-title 67
###begin article-title 68
Antigen degradation or presentation by MHC class I molecules via classical and non-classical pathways.
###end article-title 68
###begin article-title 69
Mechanisms of MHC class I-restricted antigen processing.
###end article-title 69
###begin article-title 70
Antigen processing and presentation by the class I major histocompatibility complex.
###end article-title 70
###begin article-title 71
HLA class I deficiencies.
###end article-title 71
###begin article-title 72
Clinical and immunological aspects of HLA class I deficiency.
###end article-title 72
###begin article-title 73
###xml 11 16 <span type="species:ncbi:9606">human</span>
Homozygous human TAP peptide transporter mutation in HLA class I deficiency.
###end article-title 73
###begin article-title 74
Association of HLA class I antigen deficiency related to a TAP2 gene mutation with familial bronchiectasis.
###end article-title 74
###begin article-title 75
Deficit en antigenes HLA de classe I et bronchiectasies familiales: revue de la litterature avec etude clinique et biologique.
###end article-title 75
###begin article-title 76
HLA class I deficiencies due to mutations in subunit 1 of the peptide transporter TAP1.
###end article-title 76
###begin article-title 77
###xml 94 99 <span type="species:ncbi:9606">human</span>
Splice acceptor site mutation of the transporter associated with antigen processing-1 gene in human bare lymphocyte syndrome.
###end article-title 77
###begin article-title 78
Defective expression of HLA class I antigens: a case of the bare lymphocyte syndrome without immunodeficiency.
###end article-title 78
###begin article-title 79
###xml 58 61 <span type="species:ncbi:9606">boy</span>
Defective expression of HLA class I and CD1a molecules in boy with Marfan-like phenotype and deep skin ulcers.
###end article-title 79
###begin article-title 80
###xml 72 77 <span type="species:ncbi:9606">human</span>
Molecular studies and NK cell function of a new case of TAP2 homozygous human deficiency.
###end article-title 80
###begin article-title 81
###xml 68 76 <span type="species:ncbi:9606">patients</span>
The mechanisms controlling NK cell autoreactivity in TAP2-deficient patients.
###end article-title 81
###begin article-title 82
Asymptomatic deficiency in the peptide transporter associated to antigen processing.
###end article-title 82
###begin article-title 83
Unilateral necrotising toxoplasmic retinochoroiditis as the main clinical manifestation of a peptide transporter (TAP) deficiency.
###end article-title 83
###begin article-title 84
A novel mutation for TAP deficiency and its possible association with toxoplasmosis.
###end article-title 84
###begin article-title 85
###xml 86 94 <span type="species:ncbi:9606">patients</span>
Activity and phenotype of natural killer cells in peptide transporter (TAP)-deficient patients (type I bare lymphocyte syndrome).
###end article-title 85
###begin article-title 86
###xml 26 31 <span type="species:ncbi:9606">human</span>
Inefficient protection of human TAP-deficient fibroblasts from autologous NK cell-mediated lysis by cytokines inducing HLA class I expression.
###end article-title 86
###begin article-title 87
###xml 51 59 <span type="species:ncbi:9606">patients</span>
Analysis of natural killer cells in TAP2-deficient patients: expression of functional triggering receptors and evidence for the existence of inhibitory receptor(s) that prevent lysis of normal autologous cells.
###end article-title 87
###begin article-title 88
CD94 functions as a natural killer cell inhibitory receptor for different HLA class I alleles: identification of the inhibitory form of CD94 by the use of novel monoclonal antibodies.
###end article-title 88
###begin article-title 89
###xml 4 10 4 10 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 83 86 83 86 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
CD56bright NK cells differ in their KIR repertoire and cytotoxic features from CD56dim NK cells.
###end article-title 89
###begin article-title 90
###xml 34 39 <span type="species:ncbi:9606">human</span>
Biology and clinical relevance of human natural killer cells.
###end article-title 90
###begin article-title 91
Natural killer cell subsets and development.
###end article-title 91
###begin article-title 92
Recalcitrant warts, associated with natural killer cell dysfunction, treated with systemic IFN-alpha.
###end article-title 92
###begin article-title 93
###xml 25 31 25 31 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 36 37 36 37 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
Skin infiltration of CD56bright CD16- natural killer cells in a case of X-SCID with Omenn syndrome-like manifestations.
###end article-title 93
###begin article-title 94
###xml 23 28 <span type="species:ncbi:9606">human</span>
Comparative studies of human FcRIII-positive and negative natural killer cells.
###end article-title 94
###begin article-title 95
Modification of P-selectin glycoprotein ligand-1 with a natural killer cell-restricted sulfated lactosamine creates an alternate ligand for L-selectin.
###end article-title 95
###begin article-title 96
###xml 29 30 29 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Unique subpopulations of CD56+ NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire.
###end article-title 96
###begin article-title 97
###xml 78 84 78 84 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset.
###end article-title 97
###begin article-title 98
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human natural killer cell development.
###end article-title 98
###begin article-title 99
###xml 69 72 69 72 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 81 87 81 87 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
Gene and protein characteristics reflect functional diversity of CD56dim and CD56bright NK cells.
###end article-title 99
###begin article-title 100
###xml 81 87 81 87 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 10 15 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
A case of HHV-6 associated acute necrotizing encephalopathy with increase of CD56bright NK cells.
###end article-title 100
###begin article-title 101
###xml 17 23 17 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bright</sup>
###xml 91 99 <span type="species:ncbi:9606">patients</span>
Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta.
###end article-title 101
###begin article-title 102
Licensing of natural killer cells by host major histocompatibility complex class I molecules.
###end article-title 102
###begin article-title 103
Self-tolerance of natural killer cells.
###end article-title 103
###begin article-title 104
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human NK cell education by inhibitory receptors for MHC class I.
###end article-title 104
###begin article-title 105
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cis</italic>
Cis association of Ly49A with MHC class I restricts natural killer cell inhibition.
###end article-title 105
###begin p 106
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 106
###begin p 107
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: The "Laboratoire d'Immunogenetique-Allergologie" is supported by an institutional grant from the "CRP-Sante", Luxembourg. The work of Jacques Zimmer was partially financed by a grant (BFR 96/003) from the "Ministere de la Culture, de l'Enseignement Superieur et de la Recherche" (Ministry of Culture, Higher Education and Research) of Luxembourg.
###end p 107

